Fast Market Research

New Market Study Published: Actis Biologics, Inc - Product Pipeline Review - 2012

Recently published research from Global Markets Direct, "Actis Biologics, Inc - Product Pipeline Review - 2012", is now available at Fast Market Research


Boston, MA -- (SBWIRE) -- 10/19/2012 -- Global Markets Direct's pharmaceuticals report, "Actis Biologics, Inc - Product Pipeline Review - 2012" provides data on the Actis Biologics, Inc's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Actis Biologics, Inc's corporate website, SEC filings, investor presentations and featured press releases, both from Actis Biologics, Inc and industry-specific third party sources, put together by Global Markets Direct's team.


- Actis Biologics, Inc - Brief Actis Biologics, Inc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Actis Biologics, Inc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Actis Biologics, Inc with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Actis Biologics, Inc's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get this Report

- Evaluate Actis Biologics, Inc's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Actis Biologics, Inc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Actis Biologics, Inc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Actis Biologics, Inc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Actis Biologics, Inc and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Actis Biologics, Inc - Product Pipeline Review - H2 2011
- Actis Biologics, Inc - Product Pipeline Review - Q1 2011
- Synthetic Biologics, Inc. - Product Pipeline Review - 2012
- Avaxia Biologics, Inc. - Product Pipeline Review - 2012
- Heat Biologics, Inc. - Product Pipeline Review - 2012
- Baxter International Inc. - Product Pipeline Review - 2012
- Inflammatory Bowel Disease - Pipeline Review, H1 2012
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2012
- MorphoSys AG - Product Pipeline Review - 2012
- Cancer Pain - Pipeline Review, H1 2012